NO329111B1 - Forbindelse, immunologisk adjuvanssammensetning omfattende denne, vaksinesammensetning omfattende et antigen og en adjuvansforbindelse samt anvendelse av et antigen og en adjuvansforbindelse - Google Patents

Forbindelse, immunologisk adjuvanssammensetning omfattende denne, vaksinesammensetning omfattende et antigen og en adjuvansforbindelse samt anvendelse av et antigen og en adjuvansforbindelse Download PDF

Info

Publication number
NO329111B1
NO329111B1 NO20013749A NO20013749A NO329111B1 NO 329111 B1 NO329111 B1 NO 329111B1 NO 20013749 A NO20013749 A NO 20013749A NO 20013749 A NO20013749 A NO 20013749A NO 329111 B1 NO329111 B1 NO 329111B1
Authority
NO
Norway
Prior art keywords
alkyl
alkoxy
group
optionally substituted
branched
Prior art date
Application number
NO20013749A
Other languages
English (en)
Norwegian (no)
Other versions
NO20013749D0 (no
NO20013749L (no
Inventor
Michael D Lewis
Lynn D Hawkins
Sally T Ishizaka
Pamela Mcguiness
Anneliese Nault
Jeffrey Rose
Daniel P Rossignol
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of NO20013749D0 publication Critical patent/NO20013749D0/no
Publication of NO20013749L publication Critical patent/NO20013749L/no
Publication of NO329111B1 publication Critical patent/NO329111B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/655—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms
    • C07F9/65515—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having oxygen atoms, with or without sulfur, selenium, or tellurium atoms, as the only ring hetero atoms the oxygen atom being part of a five-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/091—Esters of phosphoric acids with hydroxyalkyl compounds with further substituents on alkyl
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/06—Phosphorus compounds without P—C bonds
    • C07F9/08—Esters of oxyacids of phosphorus
    • C07F9/09—Esters of phosphoric acids
    • C07F9/10—Phosphatides, e.g. lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
NO20013749A 1999-02-01 2001-07-31 Forbindelse, immunologisk adjuvanssammensetning omfattende denne, vaksinesammensetning omfattende et antigen og en adjuvansforbindelse samt anvendelse av et antigen og en adjuvansforbindelse NO329111B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11813199P 1999-02-01 1999-02-01
PCT/US2000/002755 WO2000044758A1 (en) 1999-02-01 2000-02-01 Immunological adjuvant compound

Publications (3)

Publication Number Publication Date
NO20013749D0 NO20013749D0 (no) 2001-07-31
NO20013749L NO20013749L (no) 2001-09-25
NO329111B1 true NO329111B1 (no) 2010-08-30

Family

ID=22376670

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20013749A NO329111B1 (no) 1999-02-01 2001-07-31 Forbindelse, immunologisk adjuvanssammensetning omfattende denne, vaksinesammensetning omfattende et antigen og en adjuvansforbindelse samt anvendelse av et antigen og en adjuvansforbindelse

Country Status (21)

Country Link
US (1) US6290973B1 (de)
EP (2) EP1439184B1 (de)
JP (1) JP4698027B2 (de)
KR (1) KR100711561B1 (de)
AT (2) ATE471328T1 (de)
AU (2) AU768574B2 (de)
BR (1) BRPI0007936B8 (de)
CA (1) CA2361582C (de)
DE (2) DE60044570D1 (de)
DK (1) DK1147117T3 (de)
ES (2) ES2223464T3 (de)
FI (1) FI120689B (de)
HK (1) HK1043132B (de)
HU (1) HU226869B1 (de)
IL (3) IL144671A0 (de)
MX (1) MXPA01007760A (de)
NO (1) NO329111B1 (de)
NZ (1) NZ513259A (de)
PT (1) PT1147117E (de)
WO (1) WO2000044758A1 (de)
ZA (1) ZA200106487B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US7915238B2 (en) 1999-02-01 2011-03-29 Eisai R & D Management Co., Ltd. Immunomodulatory compounds and methods of use thereof
US6835721B2 (en) 1999-02-01 2004-12-28 Eisai Co., Ltd. Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof
YU72201A (sh) * 1999-04-28 2005-07-19 Aventis Pharma Deutschland Gmbh. Derivati di-aril kiseline kao ppar receptorski ligandi
AU2001284354A1 (en) * 2000-07-31 2002-02-13 Eisai Co. Ltd. Immunological adjuvant compounds, compositions, and methods of use thereof
SI21352A (sl) 2001-01-23 2004-06-30 Aventis Pasteur Multivalentno meningokokno cepivo iz konjugata polisaharida-proteina
ES2314087T3 (es) * 2001-03-08 2009-03-16 The Trustees Of The University Of Pennsylvania Polimeros facialmente anfifilicos como agentes antiinfecciosos.
US8481043B2 (en) * 2001-06-22 2013-07-09 Cpex Pharmaceuticals, Inc. Nasal immunization
JP2006518701A (ja) * 2002-05-24 2006-08-17 ネオファーム、インコーポレイティッド カルジオリピン組成物、その製造方法及び使用
EA200401565A1 (ru) * 2002-05-24 2005-04-28 Неофарм, Инк. Способ получения кардиолипина или аналога кардиолипина (варианты), способ получения липосомы и композиция кардиолипина для лечения заболеваний (варианты)
JP3900343B2 (ja) * 2002-09-05 2007-04-04 株式会社トリケミカル研究所 （ｒｏ）（ｒ’ｏ）（ｒ’’ｏ）ｍ＝ｏの製造方法
US20050277611A1 (en) * 2002-10-16 2005-12-15 Neopharm, Inc. Cationic cardiolipin analoges and its use thereof
EP2263687B1 (de) 2002-12-27 2015-03-25 Novartis Vaccines and Diagnostics, Inc. Immunogene zusammensetzungen enthaltend phospholipid
WO2004082634A2 (en) * 2003-03-17 2004-09-30 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers and uses thereof
JP5557415B2 (ja) 2003-06-02 2014-07-23 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 吸着させたトキソイドおよび多糖類含有抗原を含む微粒子に基づく免疫原性組成物
US7202234B2 (en) * 2003-10-24 2007-04-10 Eisai Co., Ltd. Compounds and methods for treating Toll-like receptor 2-related diseases and conditions
FR2863890B1 (fr) * 2003-12-19 2006-03-24 Aventis Pasteur Composition immunostimulante
JP5260877B2 (ja) * 2004-01-23 2013-08-14 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 面に対して両親媒性のポリアリール及びポリアリールアルキニルのポリマー及びオリゴマー並びにそれらの使用
CA2599205A1 (en) * 2005-02-25 2006-09-08 The Trustees Of The University Of Pennsylvania Facially amphiphilic polymers and oligomers, compositions thereof, and use thereof in methods of treating cancer
US20070292418A1 (en) * 2005-04-26 2007-12-20 Eisai Co., Ltd. Compositions and methods for immunotherapy
CN103285392A (zh) 2005-04-26 2013-09-11 卫材R&D管理株式会社 用于癌症免疫疗法的组合物和其用途
CA2611721C (en) 2005-06-30 2014-04-22 Eisai Co., Ltd. Compounds for preparing immunological adjuvant
EP3067048B1 (de) 2007-12-07 2018-02-14 GlaxoSmithKline Biologicals SA Zusammensetzungen zur induzierung von immunreaktionen
JP5399410B2 (ja) * 2007-12-18 2014-01-29 エーザイ・アール・アンド・ディー・マネジメント株式会社 免疫アジュバントｅ６０２０への合成前駆体のベータ−ケトアミド合成のための試薬および方法
KR101507822B1 (ko) 2008-06-04 2015-04-24 잇빤 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 불활성화 일본 뇌염 바이러스 입자를 어쥬번트로서 사용하는 방법
WO2013043580A2 (en) 2011-09-19 2013-03-28 Gencia Corporation Modified creatine compounds
US20150133551A1 (en) * 2012-05-03 2015-05-14 Beth Israel Deaconess Medical Center, Inc. Lipids That Increase Insulin Sensitivity And Methods Of Using The Same
EP2972399B1 (de) 2013-03-15 2020-09-02 Beth Israel Deaconess Medical Center, Inc. Lipide zur erhöhung der insulinempfindlichkeit und verfahren zur verwendung davon
EP3604271A1 (de) 2013-06-28 2020-02-05 Auckland Uniservices Limited Peptide für aminosäure- und peptidkonjugate und konjugationsverfahren
CN107250103A (zh) 2014-12-23 2017-10-13 玛格丽特·安妮·布林布尔 氨基酸缀合物和肽缀合物以及其用途
TW201735952A (zh) 2016-02-26 2017-10-16 瑪格蕾特 安 布萊博 胺基酸及肽共軛物以及共軛過程
WO2017214527A1 (en) 2016-06-10 2017-12-14 Beth Israel Deaconess Medical Center, Inc. Fatty acid esters of hydroxy fatty acids (fahfas) for use in the treatment of type 1 diabetes
NL2030835B1 (en) 2020-01-24 2022-12-29 Aim Immunotech Inc Methods, compositions, and vaccinces for treating a virus infection
CN113307824B (zh) 2021-04-26 2022-05-27 浙江大学 一种双亲性材料及其在制备脂质体中的应用

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2583892A (en) * 1991-09-11 1993-04-05 Pitman-Moore, Inc. Method for enhancing the immune system in a host employing liposome-encapsulated polypeptides
WO1995011700A1 (en) 1993-10-29 1995-05-04 Pharmos Corp. Submicron emulsions as vaccine adjuvants
US5961970A (en) * 1993-10-29 1999-10-05 Pharmos Corporation Submicron emulsions as vaccine adjuvants
JP3814290B2 (ja) * 1993-12-09 2006-08-23 エスクナー，ハインリッヒ 抗原用のアジュバントおよびその製法ならびに用途
GB9326253D0 (en) * 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6180111B1 (en) * 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US5834015A (en) * 1996-09-11 1998-11-10 Albany Medical College Protein-lipid vesicles and autogenous vaccine comprising the same
US6551600B2 (en) * 1999-02-01 2003-04-22 Eisai Co., Ltd. Immunological adjuvant compounds compositions and methods of use thereof
US20040006242A1 (en) * 1999-02-01 2004-01-08 Hawkins Lynn D. Immunomodulatory compounds and method of use thereof

Also Published As

Publication number Publication date
HK1043132B (en) 2005-04-01
ZA200106487B (en) 2002-08-07
US6290973B1 (en) 2001-09-18
HK1043132A1 (en) 2002-09-06
AU2004201147A1 (en) 2004-04-22
PT1147117E (pt) 2004-10-29
EP1439184B1 (de) 2010-06-16
WO2000044758A1 (en) 2000-08-03
JP2002535411A (ja) 2002-10-22
EP1147117B1 (de) 2004-06-16
KR100711561B1 (ko) 2007-04-27
NO20013749D0 (no) 2001-07-31
AU2004201147B2 (en) 2008-04-03
IL174413A0 (en) 2009-02-11
HUP0105473A2 (hu) 2002-04-29
IL144671A0 (en) 2002-05-23
CA2361582C (en) 2010-04-06
DE60011571T2 (de) 2005-08-18
EP1439184A1 (de) 2004-07-21
HUP0105473A3 (en) 2003-11-28
BRPI0007936B8 (pt) 2021-05-25
DE60044570D1 (de) 2010-07-29
FI20011593L (fi) 2001-07-31
KR20010101912A (ko) 2001-11-15
BR0007936A (pt) 2002-04-09
DK1147117T3 (da) 2004-10-25
NZ513259A (en) 2004-05-28
IL144671A (en) 2006-07-05
HU226869B1 (en) 2010-01-28
AU2867500A (en) 2000-08-18
HK1070372A1 (en) 2005-06-17
ES2347428T3 (es) 2010-10-29
BR0007936B1 (pt) 2015-03-10
MXPA01007760A (es) 2003-06-24
ATE269341T1 (de) 2004-07-15
AU768574B2 (en) 2003-12-18
JP4698027B2 (ja) 2011-06-08
EP1147117A1 (de) 2001-10-24
ATE471328T1 (de) 2010-07-15
FI120689B (fi) 2010-01-29
DE60011571D1 (de) 2004-07-22
CA2361582A1 (en) 2000-08-03
NO20013749L (no) 2001-09-25
ES2223464T3 (es) 2005-03-01

Similar Documents

Publication Publication Date Title
NO329111B1 (no) Forbindelse, immunologisk adjuvanssammensetning omfattende denne, vaksinesammensetning omfattende et antigen og en adjuvansforbindelse samt anvendelse av et antigen og en adjuvansforbindelse
US6551600B2 (en) Immunological adjuvant compounds compositions and methods of use thereof
US6835721B2 (en) Immunomodulatory compounds and methods of use thereof
US20040006242A1 (en) Immunomodulatory compounds and method of use thereof
JP4230765B2 (ja) 免疫アジュバント化合物、組成物、およびその使用方法
AU2008202882B2 (en) Immunological adjuvant compound
HK1070372B (en) Immunological adjuvant compounds

Legal Events

Date Code Title Description
MK1K Patent expired